High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications
EMHJ-Eastern Mediterranean Health Journal. 2007; 13 (5): 1053-1059
en Inglés
| IMEMR
| ID: emr-157082
ABSTRACT
As a means to manage cardiac conditions, we determined the effects of high-dose intravenous [IV] deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours [maximum 5 g] for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electro-cardiography and physical findings. There were no significant side-effects reported
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Talasemia
/
Resultado del Tratamiento
/
Deferoxamina
/
Ferritinas
/
Cardiomiopatías
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
East Mediterr Health J.
Año:
2007
Similares
MEDLINE
...
LILACS
LIS